ReviewWorld journal of gastroenterology2007
Combining chemotherapy and targeted therapies in metastatic colorectal cancer.
Review in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment.Royal Society open science · 2025Article
- A Personalized Therapeutics Approach Using anFrontiers in oncology · 2021Article
- Nuclear translocation of Atox1 potentiates activin A-induced cell migration and colony formation in colon cancer.PloS one · 2020Article
- Complete response with fluorouracil and irinotecan with a BRAFOncoTargets and therapy · 2019Article
- NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.Oncotarget · 2017Article
- Advances in radiotherapy and targeted therapies for rectal cancer.World journal of gastroenterology · 2014Review
- The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480.Pathology oncology research : POR · 2012Article
- Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis.Oncology letters · 2011Article
- Colorectal cancer and NF-κB signaling pathway.Gastroenterology and hepatology from bed to bench · 2011Article
- Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010Review
- Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.The Journal of molecular diagnostics : JMD · 2009Review
- Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?Journal of oncology · 2009Article
- Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.World journal of gastroenterology · 2008Article
- Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Current pharmaceutical design · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer remains one of the major causes of cancer death worldwide. During the past years, the development of new effective treatment options has led to a considerable improvement in the outcome of this disease. The advent of agents such as capecitabine, irinotecan, oxaliplatin, erbitux and bevacizumab has translated into median survival times in the range of 2 years. Intense efforts have focused on identifying novel agents targeting specific growth factor receptors, critical signal transduction pathways or mediators of angiogenesis. In addition, several clinical trials have suggested that some of these molecularly targeted drugs can be safely and effectively used in combination with conventional chemotherapy. In this article we review various treatment options combining cytotoxic and targeted therapies currently available for patients with metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.